Researchers reported two independent preclinical advances against triple-negative breast cancer (TNBC). One team characterized MP‑1, a wasp‑venom derived peptide that binds PD‑L1 and showed target engagement in silico and in vitro. Another group described third‑generation gallium photosensitizers that demonstrated tumor cell death in TNBC models via photodynamic therapy. Both approaches offer alternate modalities for TNBC, a subtype with limited targeted options. MP‑1 presents a novel biologic checkpoint modulator, while gallium photosensitizers provide a localized cytotoxic strategy; each could attract early‑stage biotech interest for lead optimization and IND‑enabling studies.